Aduhelm™ (aducanumab) – New drug approval
On June 7, 2021, the FDA announced the controversial approval of Biogen’s Aduhelm (aducanumab), for the treatment of Alzheimer’s disease. See the summary insights and OptumRx’s action plan for management.
Download PDF
